News

Article

Nashville Oncology Associates Now Part of The US Oncology Network

The US Oncology Network now has more than 2400 providers who treat over 1.4 million patients annually at approximately 600 sites of care in 30 states.

The US Oncology Network announced November 13, 2023, that Nashville Oncology Associates (NOA) has joined The Network, effective October 1, 2023.

“We are eager to have Nashville Oncology Associates join us on our mission to increase access to convenient, high-quality cancer care in the Nashville region,” Jason Hammonds, president, The US Oncology Network, said in a statement. “As we welcome these highly skilled cancer specialists into The Network, we extend our reach of comprehensive community-based services into Tennessee for the first time. Our goal is that our support and resources will help enhance the high-quality care NOA provides to patients in the community.”

NOA offers comprehensive cancer treatment services, treating blood cancers and disorders, as well as bone, breast, lung, reproductive, skin, gastrointestinal, colorectal, and urinary tract cancers, nurturing an atmosphere of trust and compassion. Medical oncologists Karl M. Rogers, MD, the practice president, and Carl R. Willis, MD, offer care with 2 advanced practice providers.

“Joining The Network will provide access to a wealth of operational and clinical resources that will help us continue to deliver superior care while empowering us to remain independent in today’s challenging environment,” Rogers said in the statement.

The US Oncology Network now has more than 2400 providers who treat over 1.4 million patients annually at approximately 600 sites of care in 30 states.

Related Videos
Robin Glasco, MBA
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Sandra Cuellar, PharmD
Screenshot of an interview with Nadine Barrett, PhD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Dr Bonnie Qin
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo